{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T01:15:48Z","timestamp":1760577348513},"reference-count":44,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2014,7,22]],"date-time":"2014-07-22T00:00:00Z","timestamp":1405987200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0102231","type":"journal-article","created":{"date-parts":[[2014,7,22]],"date-time":"2014-07-22T19:36:06Z","timestamp":1406057766000},"page":"e102231","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":29,"title":["Survivin as a Potential Mediator to Support Autoreactive Cell Survival in Myasthenia Gravis: A Human and Animal Model Study"],"prefix":"10.1371","volume":"9","author":[{"given":"Linda L.","family":"Kusner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Ciesielski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Marx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry J.","family":"Kaminski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Fenstermaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2014,7,22]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1172\/JCI29894","article-title":"Myasthenia gravis: past, present, and future","volume":"116","author":"BM Conti-Fine","year":"2006","journal-title":"The Journal of clinical investigation"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"6252","DOI":"10.1038\/onc.2008.302","article-title":"IAP-targeted therapies for cancer","volume":"27","author":"EC LaCasse","year":"2008","journal-title":"Oncogene"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1182\/blood.V95.4.1435.004k01_1435_1442","article-title":"Three differentially expressed survivin cDNA variants encode proteins with distinct antiapoptotic functions","volume":"95","author":"EM Conway","year":"2000","journal-title":"Blood"},{"key":"ref4","first-page":"43","article-title":"Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation","volume":"152","author":"C Adida","year":"1998","journal-title":"Am J Pathol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/25141","article-title":"Control of apoptosis and mitotic spindle checkpoint by survivin","volume":"396","author":"F Li","year":"1998","journal-title":"Nature"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1091\/mbc.E05-08-0723","article-title":"Survivin modulates microtubule dynamics and nucleation throughout the cell cycle","volume":"17","author":"J Rosa","year":"2006","journal-title":"Mol Biol Cell"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1038\/sj.onc.1203665","article-title":"Survivin initiates cell cycle entry by the competitive interaction with Cdk4\/p16(INK4a) and Cdk2\/cyclin E complex activation","volume":"19","author":"A Suzuki","year":"2000","journal-title":"Oncogene"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1042\/BJ20100814","article-title":"Survivin and IAP proteins in cell-death mechanisms","volume":"430","author":"DC Altieri","year":"2010","journal-title":"Biochem J"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1021\/bi001603q","article-title":"An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7","volume":"40","author":"S Shin","year":"2001","journal-title":"Biochemistry"},{"key":"ref10","first-page":"5315","article-title":"IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs","volume":"58","author":"I Tamm","year":"1998","journal-title":"Cancer Res"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"5000","DOI":"10.1158\/1078-0432.CCR-08-0746","article-title":"Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics","volume":"14","author":"AC Mita","year":"2008","journal-title":"Clin Cancer Res"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0165-5728(01)00389-7","article-title":"Heightened expression of survivin in activated T lymphocytes from patients with multiple sclerosis","volume":"119","author":"MK Sharief","year":"2001","journal-title":"J Neuroimmunol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"R349","DOI":"10.1186\/ar1498","article-title":"Balance between survivin, a key member of the apoptosis inhibitor family, and its specific antibodies determines erosivity in rheumatoid arthritis","volume":"7","author":"M Bokarewa","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1093\/rheumatology\/kep467","article-title":"Apoptosis in the rheumatoid arthritis synovial membrane: modulation by disease-modifying anti-rheumatic drug treatment","volume":"49","author":"MD Smith","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"ref15","first-page":"373","article-title":"Circulating survivin indicates severe course of juvenile idiopathic arthritis","volume":"26","author":"L Galeotti","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.semarthrit.2011.08.005","article-title":"High survivin levels predict poor clinical response to infliximab treatment in patients with rheumatoid arthritis","volume":"41","author":"A Isgren","year":"2012","journal-title":"Semin Arthritis Rheum"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1177\/1352458507087468","article-title":"Expression of the inhibitor of apoptosis protein family in multiple sclerosis reveals a potential immunomodulatory role during autoimmune mediated demyelination","volume":"14","author":"AL Hebb","year":"2008","journal-title":"Mult Scler"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1046\/j.1468-1331.2002.00454.x","article-title":"Upregulated survivin expression in activated T lymphocytes correlates with disease activity in multiple sclerosis","volume":"9","author":"MK Sharief","year":"2002","journal-title":"Eur J Neurol"},{"key":"ref19","first-page":"869","article-title":"Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients","volume":"61","author":"MH Andersen","year":"2001","journal-title":"Cancer Res"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1002\/jcb.23126","article-title":"Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development","volume":"112","author":"LK Aguilar","year":"2011","journal-title":"J Cell Biochem"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s00262-010-0845-x","article-title":"Antitumor cytotoxic T-cell response induced by a survivin peptide mimic","volume":"59","author":"MJ Ciesielski","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1007\/s00262-008-0510-9","article-title":"Therapeutic effect of a T helper cell supported CTL response induced by a survivin peptide vaccine against murine cerebral glioma","volume":"57","author":"MJ Ciesielski","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1586\/14760584.2014.881255","article-title":"Challenges in the development of a survivin vaccine (SurVaxM) for malignant glioma","volume":"13","author":"RA Fenstermaker","year":"2014","journal-title":"Expert Rev Vaccines"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.coph.2009.04.005","article-title":"Autoimmune disorders of the neuromuscular junction","volume":"9","author":"B Lang","year":"2009","journal-title":"Curr Opin Pharmacol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1006\/clim.1999.4807","article-title":"Animal models of myasthenia gravis","volume":"94","author":"P Christadoss","year":"2000","journal-title":"Clin Immunol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00005-011-0158-6","article-title":"Acetylcholine receptor-induced experimental myasthenia gravis: what have we learned from animal models after three decades?","volume":"60","author":"F Baggi","year":"2012","journal-title":"Archivum immunologiae et therapiae experimentalis"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1196\/annals.1405.026","article-title":"How promiscuity promotes tolerance: the case of myasthenia gravis","volume":"1132","author":"B Kyewski","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/mus.23330","article-title":"Recommendations for myasthenia gravis clinical trials","volume":"45","author":"M Benatar","year":"2012","journal-title":"Muscle & nerve"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1016\/j.ajpath.2013.02.017","article-title":"Survivin blockade sensitizes rhabdomyosarcoma cells for lysis by fetal acetylcholine receptor-redirected T cells","volume":"182","author":"K Simon-Keller","year":"2013","journal-title":"Am J Pathol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nature11556","article-title":"A call for transparent reporting to optimize the predictive value of preclinical research","volume":"490","author":"SC Landis","year":"2012","journal-title":"Nature"},{"key":"ref31","volume":"Chapter 15","unstructured":"Wu B, Goluszko E, Christadoss P (2001) Experimental autoimmune myasthenia gravis in the mouse. Curr Protoc Immunol <volume>Chapter 15<\/volume> : Unit 15 18."},{"key":"ref32","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0165-5728(96)00144-0","article-title":"Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis","volume":"71","author":"SJ Piddlesden","year":"1996","journal-title":"J Neuroimmunol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s00262-006-0138-6","article-title":"Antitumor effects of a xenogeneic survivin bone marrow derived dendritic cell vaccine against murine GL261 gliomas","volume":"55","author":"MJ Ciesielski","year":"2006","journal-title":"Cancer Immunol Immunother"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/mus.23448","article-title":"Cell surface complement regulators moderate experimental myasthenia gravis pathology","volume":"47","author":"LL Kusner","year":"2013","journal-title":"Muscle Nerve"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/ana.21536","article-title":"Novel complement inhibitor limits severity of experimentally myasthenia gravis","volume":"65","author":"J Soltys","year":"2009","journal-title":"Ann Neurol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.autrev.2013.03.010","article-title":"Etiology of myasthenia gravis: innate immunity signature in pathological thymus","volume":"12","author":"P Cavalcante","year":"2013","journal-title":"Autoimmun Rev"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1749-6632.2012.06799.x","article-title":"Thymus pathology observed in the MGTX trial","volume":"1275","author":"A Marx","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.4049\/jimmunol.171.7.3847","article-title":"Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis","volume":"171","author":"E Tuzun","year":"2003","journal-title":"J Immunol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1365-2249.2006.03205.x","article-title":"The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice","volume":"146","author":"BP Morgan","year":"2006","journal-title":"Clin Exp Immunol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s12026-013-8466-z","article-title":"B-lymphocyte tolerance and effector function in immunity and autoimmunity","volume":"57","author":"WN Khan","year":"2013","journal-title":"Immunol Res"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1001\/archneur.65.10.1358","article-title":"A potential role for B-cell activating factor in the pathogenesis of autoimmune myasthenia gravis","volume":"65","author":"S Ragheb","year":"2008","journal-title":"Arch Neurol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jneuroim.2006.05.023","article-title":"The thymus is a source of B-cell-survival factors-APRIL and BAFF-in myasthenia gravis","volume":"178","author":"M Thangarajh","year":"2006","journal-title":"J Neuroimmunol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"887","DOI":"10.4049\/jimmunol.136.3.887","article-title":"Specific activation of lymphocytes against acetylcholine receptor in the thymus in myasthenia gravis","volume":"136","author":"Y Fujii","year":"1986","journal-title":"J Immunol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.3390\/ijms15022494","article-title":"Survivin as a preferential target for cancer therapy","volume":"15","author":"M Mobahat","year":"2014","journal-title":"Int J Mol Sci"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0102231","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T11:54:45Z","timestamp":1689422085000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0102231"}},"subtitle":[],"editor":[{"given":"William","family":"Phillips","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,7,22]]},"references-count":44,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2014,7,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0102231","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,22]]}}}